Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1515718
This article is part of the Research Topic Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy: Volume III View all 7 articles

IFIT3: A Crucial Mediator in Innate Immunity and Tumor Progression with Therapeutic Implications

Provisionally accepted
日罕 乌 日罕 乌 1昊 杨 昊 杨 2*
  • 1 内蒙古医科大学, Inner Mongolia Medical University, Hohhot, China
  • 2 北京大学肿瘤医院暨内蒙古医科大学附属肿瘤医院放疗科，中国，呼和浩特、, Inner Mongolia Medical University, Hohhot, China

The final, formatted version of the article will be published soon.

    Interferon-Induced Protein with Tetratricopeptide Repeats 3 (IFIT3) plays a dual role in innate immunity and tumor immunity, functioning as both a viral defense molecule and a regulator of tumor progression. This review explores the mechanisms through which IFIT3 modulates immune responses, including interferon signaling, RIG-I-like receptors, and the NF-κB pathway. IFIT3 facilitates immune evasion and promotes inflammation-mediated tumor growth by regulating immune checkpoints and the tumor microenvironment, its emerging role as a target for cancer immunotherapy opens new avenues for therapeutic strategies. Finally, this paper underscores IFIT3's potential clinical applications in the modulation of tumor immunity, highlighting the need for further research on IFIT3-targeted therapies.

    Keywords: IFIT3, tumor immunity, Cancer Progression, innate immunity, Immunotherapy

    Received: 23 Oct 2024; Accepted: 30 Jan 2025.

    Copyright: © 2025 乌 and 杨. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: 昊 杨, 北京大学肿瘤医院暨内蒙古医科大学附属肿瘤医院放疗科，中国，呼和浩特、, Inner Mongolia Medical University, Hohhot, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.